Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Harvard Device Safety Surveillance Project Could Inform FDA Efforts

This article was originally published in The Gray Sheet

Executive Summary

A post-market safety surveillance system being piloted at five Massachusetts hospitals could inform FDA's efforts to broaden its Sentinel post-market safety system to devices, speakers at a recent Brookings Institution roundtable suggested

You may also be interested in...



Planning Board Proposes Postmarket Device Surveillance Timeline

A planning board created to develop a framework for a new U.S. medical device surveillance system has proposed a seven year plan on how to get the system up and running, which will include creating incentive systems for stakeholders as well as reducing the burden of recording and managing device data.

ICD Lead Recall Could Have Come Sooner With Novel Surveillance Tool – Study

A retrospective analysis shows that a software analytics tool would have enabled earlier detection of Medtronic’s Sprint Fidelis defibrillator lead fracture issues and an earlier recall of the device, which was withdrawn from the market in 2007.

Delving Into Device Data: FDA's Epidemiology Network Is Taking Shape

FDA's new device epidemiology network, aimed at improving device surveillance, should be fully up and running this fall.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028884

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel